Metastatic Colorectal Cancers Active Not Recruiting Phase 2 Trials for Cetuximab (DB00002)

Also known as: Colorectal Cancer Metastatic / Metastatic Colorectal Cancer / Metastatic Colorectal Cancer (MCRC) / Cancer - Metastatic Colorectal / Colorectal Cancer, Metastatic

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02404935Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)Treatment
NCT01703390Biomarker Directed Treatment in Metastatic Colorectal CancerTreatment
NCT01832467Cetuximab Rechallenge StudyTreatment
NCT01867697Nordic 8 - A Phase II TrialBasic Science
NCT02296203Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).Treatment
NCT01051167Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal CancerTreatment
NCT01892527Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High SubjectsTreatment